Suppression of B-Raf(V600E) cancers by MAPK hyper-activation

B-Raf(V600E) activates MEK/MAPK signalling and acts as oncogenic driver of a variety of cancers, including melanoma, colorectal and papillary thyroid carcinoma. Specific B-Raf(V600E) kinase inhibitors (e.g., Vemurafenib) prove initial efficacy in melanoma followed shortly by acquired resistance, whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Atiq, Rawan, Hertz, Rachel, Eldad, Sophia, Smeir, Elia, Bar-Tana, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951321/
https://www.ncbi.nlm.nih.gov/pubmed/26959890
http://dx.doi.org/10.18632/oncotarget.7909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951321/
https://www.ncbi.nlm.nih.gov/pubmed/26959890
http://dx.doi.org/10.18632/oncotarget.7909

Ejemplares similares